These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1746074)

  • 1. [Galenic innovation: Enantone monthly depot preparations].
    Hübner R
    Urologe A; 1991 May; 30(3 Suppl):7-8. PubMed ID: 1746074
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hormone kinetics in suppression with monthly Enantone depot preparations].
    Schilling A
    Urologe A; 1991 May; 30(3 Suppl):9. PubMed ID: 1746075
    [No Abstract]   [Full Text] [Related]  

  • 3. [First national Enantone Symposium. Progress in therapy of prostatic cancer. Multicenter study: long-term follow-up].
    Fornara P
    Urologe A; 1991 May; 30(3 Suppl):10-2. PubMed ID: 1746070
    [No Abstract]   [Full Text] [Related]  

  • 4. [LHRH analogs as monthly depot preparations in treatment of advanced prostate cancer].
    Urologe A; 1991 May; 30(3 Suppl):2-3. PubMed ID: 1746071
    [No Abstract]   [Full Text] [Related]  

  • 5. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Cox MC; Scripture CD; Figg WD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer.
    Schulman C; Alcaraz A; Berges R; Montorsi F; Teillac P; Tombal B
    BJU Int; 2007 Jul; 100 Suppl 1():1-5. PubMed ID: 17593201
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of metastatic prostatic cancer with monthly injections of leuprolide acetate depot].
    Jiménez Cruz JF; Vera Donoso CD; Iborra I; Solsona E; Forner E; Villavicencio H; Díaz C; González C; Rioja L; Pertusa C
    Actas Urol Esp; 1994 Feb; 18(2):90-3. PubMed ID: 7976707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect on leiomyoma volume and operability. German Leuprorelin Study Group].
    Stolz W; Pfützenreuter N
    Zentralbl Gynakol; 1997; 119(10):468-75. PubMed ID: 9432825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
    Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
    Williams G; Lindsay S; Bowsher WG
    Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro release and clinical pharmacokinetics of leuprolide from Luphere 3M Depot, a 3-month release formulation of leuprolide acetate.
    Park S; Kim DH; Kim Y; Park JH; Lee M; Song IS; Shim CK
    Drug Dev Ind Pharm; 2017 Mar; 43(3):441-447. PubMed ID: 27824264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monthly dosage form of leuprolide approved by FDA.
    Oncology (Williston Park); 1989 Apr; 3(4):139. PubMed ID: 2518158
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
    Isurugi K; Niijima T; Akaza H; Aso Y; Koiso K; Fuse M; Okada K; Usami M; Ohashi T; Ueda T;
    J Chemother; 1989 Jul; 1(4 Suppl):1237-41. PubMed ID: 16312848
    [No Abstract]   [Full Text] [Related]  

  • 14. 'Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostate.
    Sharifi R; Soloway M; Clayton M; Mounzer A; Strub M; Siami P; Lee M
    Anticancer Drugs; 1990 Oct; 1(1):29-31. PubMed ID: 2131032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of long-term follow-up in treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enantone-Gyn monthly depot)].
    Regidor PA; Schindler AE; Bühler K; Gerhard I; Kimmig R; Meinen K; Hoffmann G; Lübben G; Kienle E
    Zentralbl Gynakol; 1996; 118(5):283-90. PubMed ID: 8701625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe.
    Tunn UW; Wiedey K
    Prostate Cancer Prostatic Dis; 2009; 12(1):83-7. PubMed ID: 19030021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Injection systems for two luteinising hormone-releasing hormone agonists: a comparative assessment of administration times and nurses' perceptions.
    Morgan G; Cooley C
    Eur J Oncol Nurs; 2005 Dec; 9(4):334-40. PubMed ID: 16298160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.